Differences

This shows you the differences between two versions of the page.

--- endocrine:sglt2:empagliflozin [2026/02/13 00:08] – created andrew2393cns
+++ endocrine:sglt2:empagliflozin [2026/02/13 00:08] (current) – [Empagliflozin vs Dapagliflozin] andrew2393cns
@@ Line 120: / Line 120: @@
 [[endocrine:sglt2:dapagliflozin|Dapagliflozin]]:
-• Strong HF data (DAPA-HF)
+  * • Strong HF data (DAPA-HF)
-• Strong CKD data (DAPA-CKD)
+  * • Strong CKD data (DAPA-CKD)
 Empagliflozin:
-• First to show CV mortality reduction
+  * • First to show CV mortality reduction
-• Similar HF and renal benefit
+  * • Similar HF and renal benefit
 Clinically interchangeable in most HF patients.